RBC Capital initiated coverage with an Outperform rating and a $312 target, emphasizing BeiGene's promising revenue growth and strong oncology pipeline. These developments reflect a broad confidence in BeiGene's strategic direction and financial health. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.